Li Bowen, Jiang Allen Yujie, Raji Idris, Atyeo Caroline, Raimondo Theresa M, Gordon Akiva G R, Rhym Luke H, Samad Tahoura, MacIsaac Corina, Witten Jacob, Mughal Haseeb, Chicz Taras M, Xu Yue, McNamara Ryan P, Bhatia Sangeeta, Alter Galit, Langer Robert, Anderson Daniel G
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nat Biomed Eng. 2025 Feb;9(2):167-184. doi: 10.1038/s41551-023-01082-6. Epub 2023 Sep 7.
To elicit optimal immune responses, messenger RNA vaccines require intracellular delivery of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA vaccine consisting of lipid nanoparticles encapsulating an mRNA-encoded antigen, optimized for efficient mRNA delivery and for the enhanced activation of innate and adaptive responses. We optimized the vaccine by screening a library of 480 biodegradable ionizable lipids with headgroups adjuvanted with cyclic amines and by adjuvanting the mRNA-encoded antigen by fusing it with a natural adjuvant derived from the C3 complement protein. In mice, intramuscular or intranasal administration of nanoparticles with the lead ionizable lipid and with mRNA encoding for the fusion protein (either the spike protein or the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) increased the titres of antibodies against SARS-CoV-2 tenfold with respect to the vaccine encoding for the unadjuvanted antigen. Multiply adjuvanted mRNA vaccines may improve the efficacy, safety and ease of administration of mRNA-based immunization.
为引发最佳免疫反应,信使核糖核酸(mRNA)疫苗需要将mRNA递送至细胞内,并谨慎使用佐剂。在此,我们报告一种多重佐剂mRNA疫苗,其由包裹mRNA编码抗原的脂质纳米颗粒组成,该疫苗针对高效的mRNA递送以及增强先天免疫和适应性免疫反应的激活进行了优化。我们通过筛选一个包含480种可生物降解的可电离脂质的文库(其头部基团用环胺佐剂化),并通过将mRNA编码抗原与源自C3补体蛋白的天然佐剂融合来佐剂化该抗原,从而对疫苗进行了优化。在小鼠中,肌肉注射或鼻内给予含有主要可电离脂质以及编码融合蛋白(严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的刺突蛋白或受体结合结构域)的mRNA的纳米颗粒,相对于编码未佐剂化抗原的疫苗,抗SARS-CoV-2抗体滴度提高了十倍。多重佐剂mRNA疫苗可能会提高基于mRNA的免疫接种的效力、安全性和给药便利性。
ACS Appl Mater Interfaces. 2025-1-22
J Nanobiotechnology. 2024-11-16
Biochem Biophys Res Commun. 2025-2
J Control Release. 2025-2-10
Acta Pharm Sin B. 2025-4
Proc Natl Acad Sci U S A. 2025-2-4
Nat Biotechnol. 2024-12-10
J Nanobiotechnology. 2024-11-16
Nat Biotechnol. 2023-12
Nat Biotechnol. 2024-6
Nat Biotechnol. 2024-3
Sci Immunol. 2022-11-18
Nat Biotechnol. 2022-6